spacer
home > epc > spring 2009 > non-clinical acceleration
PUBLICATIONS
European Pharmaceutical Contractor

Non-Clinical Acceleration

In the course of the development of a new drug, the selection of the most promising molecule from a series of closely related molecules for further development is timeconsuming and expensive. Data provided by pharmacodynamic studies conducted in vitro or in vivo, or by pharmacological studies in test animals, are often inadequate to differentiate with sufficient reliability those molecules which should be excluded from further development. When considering start-up and smaller companies in particular, it is extremely important to focus as early as possible on the most promising candidate for further development, in order to save time, resources and costs.

In such a case, it must be emphasised that the most reliable information about a drug can really only be generated using human subjects (volunteers or patients). The results obtained when going first time in man are therefore of pivotal relevance, and enable a sponsor to get a much more accurate picture of the pharmacological potential of a molecule.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Ruediger Haecker is a qualified physician, specialising in biochemistry. He completed his academic education in Leipzig and Magdeburg, and has held academic positions as a Lecturer and Full Professor of Biochemistry in Dresden and Leipzig, Germany. Since 1990, Ruediger has held several positions researching the developments of human and veterinary pharmaceuticals. He has worked on around 30 scientific publications and written more than 150 papers and presentations. Ruediger joined Harlan Laboratories Ltd in 2001, working as a Scientific Advisor in non-clinical development, specialising in international drug regulatory affairs.

Steve Dean has a background in genetics and cell biology, and holds a PhD in oncology from the Paterson Laboratories in Manchester, UK. Following postdoctoral work both in the US and the UK, he began his industrial career as a Genetic Toxicologist at Covance, holding positions as Head of Genetic Toxicology and managing Toxicology Operations in Harrogate. In 1999 he took the opportunity to work in Italy as Managing Director of RTC in Rome, then returned in 2002 to the UK as Group Sales Director for HLS in Cambridgshire. In recent years he has continued to participate in scientific activities, is a past President of the UK Environmental Mutagen Society and a Eurotox-registered toxicologist. He recently relocated to Switzerland as Director of Business Development for Harlan Laboratories CRS Division.

spacer
Ruediger Haecker
spacer
spacer
spacer
Steve Dean
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement